Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Synthesis and biological evaluation of novel phosphatidylinositol 3-kinase inhibitors: Solubilized 4-substituted benzimidazole analogs of 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).

Rewcastle GW, Gamage SA, Flanagan JU, Kendall JD, Denny WA, Baguley BC, Buchanan CM, Chao M, Kestell P, Kolekar S, Lee WJ, Lill CL, Malik A, Singh R, Jamieson SM, Shepherd PR.

Eur J Med Chem. 2013 Jun;64:137-47. doi: 10.1016/j.ejmech.2013.03.038. Epub 2013 Apr 6.

PMID:
23644197
2.

Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics.

Lukka PB, Paxton JW, Kestell P, Baguley BC.

Cancer Chemother Pharmacol. 2012 Jul;70(1):151-60. doi: 10.1007/s00280-012-1892-0. Epub 2012 Jun 3.

PMID:
22660735
3.

A rapid LC-MS/MS method for the quantitation of a series of benzonaphthyridine derivatives: application to in vivo pharmacokinetic and lipophilicity studies in drug development.

Lukka PB, Paxton JW, Atwell GJ, Kestell P, Baguley BC.

J Pharm Biomed Anal. 2012 Apr 7;63:9-16. doi: 10.1016/j.jpba.2012.01.022. Epub 2012 Jan 28.

PMID:
22361659
4.

Comparative effects in rats of intact wheat bran and two wheat bran fractions on the disposition of the mutagen 2-amino-3-methylimidazo[4,5-f]quinoline.

Ferguson LR, Harris PJ, Kestell P, Zhu S, Munday R, Munday CM.

Mutat Res. 2011 Nov 1;716(1-2):59-65. doi: 10.1016/j.mrfmmm.2011.08.005. Epub 2011 Sep 16.

PMID:
21939672
5.

Therapeutic reactivation of mutant p53 protein by quinazoline derivatives.

Sutherland HS, Hwang IY, Marshall ES, Lindsay BS, Denny WA, Gilchrist C, Joseph WR, Greenhalgh D, Richardson E, Kestell P, Ding A, Baguley BC.

Invest New Drugs. 2012 Oct;30(5):2035-45. doi: 10.1007/s10637-011-9744-z. Epub 2011 Sep 13.

PMID:
21912889
6.

Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).

Rewcastle GW, Gamage SA, Flanagan JU, Frederick R, Denny WA, Baguley BC, Kestell P, Singh R, Kendall JD, Marshall ES, Lill CL, Lee WJ, Kolekar S, Buchanan CM, Jamieson SM, Shepherd PR.

J Med Chem. 2011 Oct 27;54(20):7105-26. doi: 10.1021/jm200688y. Epub 2011 Sep 27.

PMID:
21882832
7.

Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice.

Lukka PB, Paxton JW, Kestell P, Baguley BC.

Cancer Chemother Pharmacol. 2010 May;65(6):1145-52. doi: 10.1007/s00280-009-1123-5. Epub 2009 Sep 23.

PMID:
19774378
8.

Development and validation of a liquid chromatography-mass spectrometry (LC-MS) assay for the determination of the anti-cancer agent N-[2-(dimethylamino)ethyl]-2,6-dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide (SN 28049).

Lukka PB, Kestell P, Paxton JW, Baguley BC.

J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Nov 15;875(2):368-72. doi: 10.1016/j.jchromb.2008.09.023. Epub 2008 Sep 26.

PMID:
18926778
9.

Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs.

Wang LC, Ching LM, Paxton JW, Kestell P, Sutherland R, Zhuang L, Baguley BC.

Invest New Drugs. 2009 Jun;27(3):280-4. doi: 10.1007/s10637-008-9167-7. Epub 2008 Aug 12.

PMID:
18696010
10.

Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial.

Jameson MB, Baguley BC, Kestell P, Zhao L, Paxton JW, Thompson PI, Waller S; Cancer Research (UK) Phase I/II Trials Committee.

Cancer Chemother Pharmacol. 2007 Apr;59(5):681-7. Epub 2006 Sep 23.

PMID:
17021822
12.

5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.

McKeage MJ, Fong P, Jeffery M, Baguley BC, Kestell P, Ravic M, Jameson MB.

Clin Cancer Res. 2006 Mar 15;12(6):1776-84.

13.

Inhibition of human CYP1A2 oxidation of 5,6-dimethyl-xanthenone-4-acetic acid by acridines: a molecular modelling study.

Paxton JW, Kestell P, Chiang D, Zhou S, Lewis DF.

Clin Exp Pharmacol Physiol. 2005 Aug;32(8):633-9.

PMID:
16120190
14.

Transport of thalidomide by the human intestinal caco-2 monolayers.

Zhou S, Li Y, Kestell P, Schafer P, Chan E, Paxton JW.

Eur J Drug Metab Pharmacokinet. 2005 Jan-Jun;30(1-2):49-61.

PMID:
16010862
15.
16.

Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells.

Zhou S, Feng X, Kestell P, Paxton JW, Baguley BC, Chan E.

Eur J Pharm Sci. 2005 Apr;24(5):513-24.

PMID:
15784341
17.

Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients.

Liu JJ, Kestell P, Findlay M, Riley G, Ackland S, Simpson A, Isaacs R, McKeage MJ.

Clin Exp Pharmacol Physiol. 2004 Oct;31(10):677-82.

PMID:
15554907
18.

Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients.

Chung F, Lu J, Palmer BD, Kestell P, Browett P, Baguley BC, Tingle M, Ching LM.

Clin Cancer Res. 2004 Sep 1;10(17):5949-56.

19.
20.

Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites.

Wang LC, Reddy CB, Baguley BC, Kestell P, Sutherland R, Ching LM.

Biochem Pharmacol. 2004 Mar 1;67(5):937-45.

PMID:
15104247
21.

Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans.

Lu J, Helsby N, Palmer BD, Tingle M, Baguley BC, Kestell P, Ching LM.

J Pharmacol Exp Ther. 2004 Aug;310(2):571-7. Epub 2004 Apr 9.

PMID:
15075384
22.

Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor.

Chung F, Wang LC, Kestell P, Baguley BC, Ching LM.

Cancer Chemother Pharmacol. 2004 May;53(5):377-83. Epub 2004 Jan 13.

PMID:
15060740
23.
24.
26.

Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent.

Jameson MB, Thompson PI, Baguley BC, Evans BD, Harvey VJ, Porter DJ, McCrystal MR, Small M, Bellenger K, Gumbrell L, Halbert GW, Kestell P; Phase I/II Trials Committee of Cancer Research UK.

Br J Cancer. 2003 Jun 16;88(12):1844-50.

27.
28.

Thalidomide metabolites in mice and patients with multiple myeloma.

Lu J, Palmer BD, Kestell P, Browett P, Baguley BC, Muller G, Ching LM.

Clin Cancer Res. 2003 May;9(5):1680-8.

30.

Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection.

Zhou S, Li Y, Kestell P, Paxton JW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Feb 25;785(1):165-73.

PMID:
12535849
33.

Fate of the anthelmintic, phenothiazine, in man.

Mitchell SC, Kestell P, Steventon GB, Waring RH.

Xenobiotica. 2002 Sep;32(9):771-82.

PMID:
12396274
34.

6-methylhydroxylation of the anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by flavin-containing monooxygenase 3.

Zhou S, Kestell P, Paxton JW.

Eur J Drug Metab Pharmacokinet. 2002 Jul-Sep;27(3):179-83.

PMID:
12365199
35.

Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide.

Ding Q, Kestell P, Baguley BC, Palmer BD, Paxton JW, Muller G, Ching LM.

Cancer Chemother Pharmacol. 2002 Sep;50(3):186-92. Epub 2002 Jul 6.

PMID:
12203100
36.

5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.

Zhou S, Kestell P, Baguley BC, Paxton JW.

Invest New Drugs. 2002 Aug;20(3):281-95. Review.

PMID:
12201491
37.

The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice.

Zhao L, Ching LM, Kestell P, Baguley BC.

Br J Cancer. 2002 Aug 12;87(4):465-70.

38.
39.

Strain differences in the liver microsomal metabolism of the experimental anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in mice.

Zhou S, Kestell P, Paxton JW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Sep 5;776(2):231-6.

PMID:
12138005
40.

Thalidomide in cancer treatment: a potential role in the elderly?

Zhou S, Kestell P, Tingle MD, Paxton JW.

Drugs Aging. 2002;19(2):85-100. Review.

PMID:
11950376
42.

High-throughput screening of potential inhibitors for the metabolism of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.

Zho S, Chiang D, Chin R, Kestell P, Paxton JW.

J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Feb 5;767(1):19-26.

PMID:
11863291
43.

Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

Zhou S, Kestell P, Tingle MD, Paxton JW.

Cancer Chemother Pharmacol. 2002 Feb;49(2):126-32. Epub 2001 Oct 24.

PMID:
11862426
44.

Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.

Zhao L, Kestell P, Ching LM, Baguley BC.

Cancer Chemother Pharmacol. 2002 Jan;49(1):20-6.

PMID:
11855749
45.

Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents.

Kestell P, Zhao L, Jameson MB, Stratford MR, Folkes LK, Baguley BC.

Clin Chim Acta. 2001 Dec;314(1-2):159-66.

PMID:
11718691
46.

Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans.

Zhou SF, Paxton JW, Tingle MD, Kestell P, Jameson MB, Thompson PI, Baguley BC.

Xenobiotica. 2001 May;31(5):277-93.

PMID:
11491389
47.
48.

A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.

Zhou S, Kestell P, Tingle MD, Ching LM, Paxton JW.

Cancer Chemother Pharmacol. 2001 Jun;47(6):541-4.

PMID:
11459209
49.

Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).

Zhao L, Kestell P, Philpott M, Ching LM, Zhuang L, Baguley BC.

Cancer Chemother Pharmacol. 2001 Jun;47(6):491-7.

PMID:
11459201

Supplemental Content

Loading ...
Support Center